Eesti - eesti - Ravimiamet

norit nederland b.v. - aktiveeritud süsi - suukaudse suspensiooni graanulid - 50g 61.5g 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antitrombootilised ained - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. ennetamine insuldi ja süsteemse emboolia täiskasvanud patsientidel, kellel on mitte-valvulaarne kodade virvendus (nvaf), ühe või mitme riskifaktorid, nagu eelnev insult või mööduv ischaemic attack (tia); vanus ≥ 75 aastat; hüpertensioon; suhkurtõbi; sümptomaatiline südamepuudulikkus (nyha klass ≥ ii). ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel (vt lõik 4. 4 haemodynamically ebastabiilne pe patsientidel). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel (vt lõik 4. 4 haemodynamically ebastabiilne pe patsientidel).

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - karbamasepiin - toimeainet prolongeeritult vabastav tablett - 600mg 50tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - karbamasepiin - toimeainet prolongeeritult vabastav tablett - 300mg 50tk

Eesti - eesti - Ravimiamet

jubilant pharmaceuticals nv - okskarbasepiin - õhukese polümeerikattega tablett - 600mg 20tk; 600mg 90tk; 600mg 200tk; 600mg 60tk; 600mg 30tk; 600mg 100tk; 600mg 10tk; 600mg 50tk

Eesti - eesti - Ravimiamet

jubilant pharmaceuticals nv - okskarbasepiin - õhukese polümeerikattega tablett - 300mg 200tk; 300mg 60tk; 300mg 90tk; 300mg 20tk; 300mg 10tk; 300mg 30tk; 300mg 50tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - okskarbasepiin - õhukese polümeerikattega tablett - 150mg 100tk; 150mg 50tk; 150mg 56tk; 150mg 200tk; 150mg 500tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - okskarbasepiin - õhukese polümeerikattega tablett - 300mg 200tk; 300mg 30tk; 300mg 50tk; 300mg 1tk; 300mg 56tk; 300mg 500tk; 300mg 100tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - okskarbasepiin - õhukese polümeerikattega tablett - 600mg 1tk; 600mg 100tk; 600mg 50tk; 600mg 56tk; 600mg 200tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.